Sareum Holdings receives milestone payment
9th Jan 2017 16:39
(ShareCast News) - Sareum Holdings, an AIM listed specialist cancer drug discovery and development company, has announced the attainment of a $2m milestone payment as part of the Chk1 license agreement between its co-investment partner the CRT Pioneer Fund and Sierra Oncology, formerly known as ProN
Read moreSareum reports positive results from TYK2 programme
24th Oct 2016 15:02
(ShareCast News) - Specialist cancer drug discovery and development business Sareum announced a successful conclusion from its feasibility study into the potential for its TYK2 programme lead molecules to treat T-Cell Acute Lymphoblastic Leukaemia (T-ALL) on Monday. The AIM-traded company said the i
Read moreSareum Holdings granted patents in Japan and Singapore
17th Oct 2016 14:16
(ShareCast News) - Specialist cancer drug discovery and development company Sareum announced on Monday that the Japan and Singapore Patent Offices have issued notifications that patents will be granted for inventions associated with its Aurora+FLT3 kinase inhibitor programme. The AIM-traded firm sai
Read moreSareum programme receives patents in Hong Kong and China
3rd Aug 2016 14:56
(ShareCast News) - Specialist cancer drug discovery and development business Sareum announced on Wednesday that the Chinese Patent Office and the Hong Kong Patents Registry have issued notifications that patents will be granted for inventions associated with the company's Aurora+FLT3 Kinase Inhibito
Read moreSareum cancer drug candidate gets MHRA trial approval
5th Apr 2016 12:33
(ShareCast News) - Sareum Holdings was pressing ahead with one of its cancer drug programmes on Tuesday, having received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for the Clinical Trial Applications submitted for CHK1 inhibitor drug candidate CCT245737. The AIM-tra
Read moreSareum inches closer to drug breakthrough
24th Feb 2016 12:25
(ShareCast News) - Sareum Holdings was still running on the smell of an oily rag in its interim report on Wednesday, but the company was confident it was heading towards a breakthrough in its durgs under development. The AIM-traded cancer drug discovery and development business saw no revenue during
Read moreSareum reports progress with psoriasis drug development programme
1st Oct 2014 11:54
Drug development firm Sareum and its partner SRI International have reported progress with its drug development programme for the autoimmune disease psoriasis. Psoriasis can occur when the production of cytokines is not properly regulated and immune cells are consequently overly activated. The cyct
Read moreSareum Holdings does cancer drug deal in China
2nd Dec 2013 14:17
Cancer drug developer Sareum Holdings has signed a deal with a Chinese medical university to progress its Aurora+FLT3 cancer programme. Sareum has granted the Hebei Medical University Biomedical Engineering Center exclusive rights to carry out pre-clinical and clinical studies within Greater China
Read moreSareum raises funds for further drug development
1st Nov 2013 12:34
Sareum Holdings, a cancer drug discovery and development business, has placed 278.5m shares at 0.6p each, it announced Friday. The group raised a conditional £1.67m before expenses from the placing, which it said was oversubscribed. The proceeds of the placing will provide funds to facilitate the
Read moreSareum Holdings and SRI International develop drug for inflammatory diseases
22nd Apr 2013 08:06
Cancer drug discovery business Sareum Holdings has entered into a co-development agreement with research institute SRI International. The two have joined forces to advance Sareum's Tyrosine Kinase 2 (TYK2) small molecule drug discovery programme for readiness in human clinical trials. Research wi
Read moreSareum shares fall following interims and research update
18th Feb 2013 08:21
Shares in AIM-listed Sareum Holdings, the specialist cancer drug discovery business, fell sharply on Monday morning after the company unveiled its half yearly results alongside a research update. Cash at bank as of December 31st fell 28% to £380,000 and the company reported a loss on ordinary activ
Read moreSareum share price climbs on US patent grant announcement
7th Feb 2013 08:27
The share price of AIM-listed specialist cancer drug discovery business Sareum Holdings jumped sharply on Thursday after the company announced that a patent was due to be awarded in the US for one of its key drug discovery inventions. The patent, which is expected on February 19th, relates to compo
Read moreSareum share price plummets ahead of AGM
12th Dec 2012 10:40
The likelihood that specialist cancer drug discovery business Sareum will conclude a deal to commercialise a research programme this year has fallen, according to an announcement made ahead of its annual general meeting (AGM) on Wednesday morning. During the AGM, Dr. Paul Harper, the company's Chai
Read moreSmall caps round-up: Sareum, Lonrho, FFastFill
10th Sep 2012 14:37
Sareum, a specialist cancer drug discovery business, has entered into a four million pound Standby Equity Distribution Agreement (SEDA) with YA Global Master, an investment fund to provide a flexible source of future funding to the company to support its on-going drug research activities. It will a
Read moreSmall caps round-up: YouGov, Sareum and InterQuest...
7th Aug 2012 11:25
Environmental Recycling Technologies, which owns the rights to the Powder Impression Moulding (PIM) process which is capable of converting mixed waste plastics into commercially viable products, has confirmed that its US parent application, entitled 'Process for Forming Plastic, Apparatuses for Form
Read more